Name
Purdue University Globle
NU577 NP II Clinical – Women’s Health Focus
Prof. Name
Date
Sexually transmitted infections (STIs) are managed through accurate diagnosis, appropriate antimicrobial treatment, sexual partner management, and patient education. The recommended treatment depends on the specific infection, disease stage, pregnancy status, and clinical presentation. For common uncomplicated infections, metronidazole is used for trichomoniasis, benzathine penicillin G is the preferred treatment for certain stages of syphilis, and doxycycline is the recommended first-line treatment for uncomplicated chlamydia in most nonpregnant adults. Early recognition and treatment help reduce transmission and prevent complications. This NU577 Unit 5 assignment reviews the clinical manifestations, diagnostic evaluation, treatment, patient counseling, and referral considerations associated with common STIs.
Sexually transmitted infections are a significant public health concern because they can affect reproductive health, pregnancy outcomes, and overall well-being. Common bacterial and parasitic STIs include chlamydia, syphilis, and trichomoniasis. Some infections produce noticeable symptoms, while others remain asymptomatic and are discovered during routine screening.
Healthcare providers in primary care, community health, and sexual health settings have an important role in identifying infections and providing evidence-based care. Effective STI management involves more than prescribing medication. It also requires sexual history assessment, appropriate laboratory testing, treatment adherence counseling, partner services, and follow-up when indicated.
The CDC STI Treatment Guidelines provide evidence-based recommendations for the diagnosis and treatment of sexually transmitted infections. Clinicians should also consider local public health requirements and current institutional protocols when developing a treatment plan.
Trichomoniasis is a sexually transmitted infection caused by the protozoan parasite Trichomonas vaginalis. It is a common nonviral STI that can affect both women and men. Although many infected individuals do not experience symptoms, symptomatic patients may present with vaginal irritation, discharge, or discomfort during urination.
The clinical presentation of trichomoniasis varies among patients. Some individuals remain asymptomatic, while others develop noticeable genitourinary symptoms.
Common symptoms in women include:
Vaginal itching or irritation.
Increased vaginal discharge.
Vaginal discomfort.
Dysuria, or painful urination.
Discomfort during sexual intercourse.
Physical examination may reveal vulvovaginal inflammation, abnormal vaginal discharge, or a strawberry cervix. A strawberry cervix refers to punctate cervical hemorrhages that may be visible during examination. This finding can support clinical suspicion but is not present in every patient.
Laboratory testing is necessary to confirm trichomoniasis because symptoms can overlap with other vaginal infections, including bacterial vaginosis and vulvovaginal candidiasis.
Common diagnostic methods include wet mount microscopy and nucleic acid amplification testing (NAAT). Wet mount microscopy may identify motile trichomonads, but its sensitivity is relatively low. NAAT provides greater sensitivity and is commonly preferred when available.
Healthcare providers should select the diagnostic test based on clinical presentation, available resources, and the patient’s circumstances.
The CDC recommends oral metronidazole 500 mg twice daily for 7 days for women with trichomoniasis. This multidose regimen is more effective than a single 2-g dose in women, particularly in reducing repeat infection.
For men with uncomplicated trichomoniasis, the CDC recommends metronidazole 2 g orally in a single dose. Alternative regimens may be considered when clinically appropriate.
Treatment selection should account for allergies, medication interactions, pregnancy, and other patient-specific factors.
Patient education is essential to prevent reinfection and reduce transmission. Healthcare providers should explain that completing the prescribed medication is important, even when symptoms improve.
Patients should be advised to:
Avoid sexual activity until they and their sexual partners have completed treatment and symptoms have resolved.
Ensure current and recent sexual partners receive evaluation and treatment.
Take medication exactly as prescribed.
Use condoms consistently and correctly to reduce STI risk.
Return for evaluation if symptoms persist or recur.
Because reinfection is common, sexually active women treated for trichomoniasis should be retested approximately 3 months after treatment. This is a retest for repeat infection, not a routine test-of-cure immediately after treatment.
Uncomplicated trichomoniasis can usually be managed in primary care. Referral or additional evaluation may be appropriate when patients have persistent symptoms, suspected treatment failure, medication intolerance, recurrent infection, or another suspected genital infection.
Syphilis is a bacterial STI caused by Treponema pallidum. It is a systemic infection that progresses through different clinical stages. Without treatment, syphilis can cause serious complications involving the nervous system, cardiovascular system, and other organs.
The stage of syphilis is important because treatment recommendations depend on the duration and classification of the infection. Patients may also have latent disease, in which symptoms are absent despite ongoing infection.
Syphilis may present with different findings depending on the stage.
Primary syphilis commonly causes a painless chancre, or ulcer, at the site of infection. Regional lymphadenopathy may also occur.
Secondary syphilis may produce systemic and mucocutaneous findings, including:
Skin rash, including involvement of the palms and soles.
Fever.
Fatigue.
Generalized lymphadenopathy.
Mucous membrane lesions.
Condyloma lata, which are broad, moist lesions associated with secondary syphilis.
Latent syphilis does not produce clinical symptoms, but laboratory testing remains positive.
Tertiary syphilis may develop years after untreated infection and can affect the cardiovascular system, nervous system, and other organs.
Patients with visual changes, hearing loss, neurological symptoms, or signs of meningitis require prompt assessment for possible neurosyphilis, ocular syphilis, or otosyphilis.
Syphilis diagnosis typically involves a combination of serologic tests.
Nontreponemal tests include:
Rapid plasma reagin (RPR).
Venereal Disease Research Laboratory (VDRL) test.
Treponemal tests include assays such as the T. pallidum particle agglutination assay (TP-PA) and other treponemal-specific tests.
A presumptive diagnosis generally requires both a nontreponemal and a treponemal test. RPR or VDRL titers are useful for monitoring treatment response.
Patients with suspected neurosyphilis require additional evaluation, which may include cerebrospinal fluid examination, based on the clinical presentation.
Treatment for syphilis depends on the stage of disease.
For primary, secondary, and early latent syphilis, the CDC recommends:
Benzathine penicillin G 2.4 million units administered intramuscularly as a single dose.
For late latent syphilis or latent syphilis of unknown duration, the recommended regimen is:
Benzathine penicillin G 7.2 million units total, administered as 2.4 million units intramuscularly once weekly for 3 weeks.
Neurosyphilis, ocular syphilis, and otosyphilis require a different penicillin regimen and specialist involvement.
Pregnant patients with syphilis should receive penicillin treatment appropriate to the stage of infection. Penicillin is the only known effective antimicrobial therapy for preventing congenital syphilis.
Patients should understand the importance of completing treatment and attending follow-up appointments. Healthcare providers should explain that treatment prevents progression and transmission but may not reverse all damage caused by longstanding infection.
Important counseling points include:
Notify sexual partners so they can receive appropriate evaluation and treatment.
Avoid sexual activity until the clinician advises that it is safe and relevant treatment has been completed.
Use condoms consistently to reduce the risk of acquiring or transmitting STIs.
Report new neurological symptoms, vision changes, or hearing changes promptly.
Understand the possibility of a Jarisch-Herxheimer reaction after treatment.
The Jarisch-Herxheimer reaction is an acute inflammatory response that may occur within the first 24 hours after syphilis treatment. It can cause fever, chills, headache, muscle aches, and malaise. Patients should be informed that this reaction is associated with treatment and is not the same as a penicillin allergy.
Syphilis follow-up depends on the stage of infection. Patients with primary or secondary syphilis are generally followed clinically and serologically at 6 and 12 months. Additional follow-up may be needed when symptoms persist or reinfection is suspected.
Patients with latent syphilis generally require serologic follow-up at 6, 12, and 24 months.
Syphilis is a reportable infection in the United States. Healthcare providers should follow applicable state and local reporting requirements and coordinate partner notification through public health services.
Referral to infectious disease, neurology, ophthalmology, or other specialists may be necessary when neurological, ocular, or complicated disease is suspected.
Chlamydia is a common bacterial STI caused by Chlamydia trachomatis. It frequently affects adolescents and young adults and may occur without noticeable symptoms. Asymptomatic infection is clinically important because untreated chlamydia can lead to pelvic inflammatory disease, infertility, ectopic pregnancy, and other reproductive complications.
Many patients with chlamydia do not report symptoms. When symptoms occur, they may include:
Abnormal vaginal discharge.
Dysuria.
Pelvic or lower abdominal discomfort.
Pain during sexual intercourse.
Abnormal vaginal bleeding, including bleeding after intercourse.
Men may experience urethral discharge, dysuria, or testicular discomfort.
Because symptoms can be mild or absent, screening is an important part of chlamydia prevention and early diagnosis.
Nucleic acid amplification testing (NAAT) is the preferred diagnostic method for chlamydia because of its high sensitivity and specificity.
Specimen collection may include:
Vaginal swabs.
Endocervical swabs when clinically indicated.
First-catch urine specimens.
Urethral specimens in selected patients.
Vaginal swabs are commonly used for screening in women. Patient-collected vaginal swabs may be appropriate when validated collection methods are available.
Healthcare providers should also consider testing for other STIs, including gonorrhea, HIV, and syphilis, based on the patient’s sexual history and risk factors.
For uncomplicated chlamydial infection in most nonpregnant adults and adolescents, the CDC recommends:
Doxycycline 100 mg orally twice daily for 7 days.
Alternative treatments may be used when doxycycline is contraindicated or unsuitable. Azithromycin 1 g orally in a single dose or levofloxacin 500 mg orally once daily for 7 days may be considered in selected circumstances.
Doxycycline is not the preferred treatment during pregnancy. Pregnant patients should receive a pregnancy-appropriate regimen, commonly azithromycin, under clinician guidance.
Patients should be taught how to prevent reinfection and recognize symptoms that require further evaluation.
Important teaching points include:
Complete the full prescribed antibiotic regimen.
Avoid sexual activity until the 7-day doxycycline course is completed and symptoms have resolved, and until sexual partners have been treated.
Encourage recent sexual partners to receive evaluation and treatment.
Use condoms consistently and correctly.
Return for care if symptoms persist, worsen, or recur.
Patients should seek prompt medical attention for pelvic pain, fever, persistent discharge, painful intercourse, or worsening urinary symptoms. These findings may indicate complications such as pelvic inflammatory disease.
Routine test-of-cure is not recommended for most nonpregnant patients treated for uncomplicated chlamydia. However, test-of-cure is recommended approximately 4 weeks after treatment during pregnancy. Retesting approximately 3 months after treatment is recommended for most patients because repeat infection is common.
Uncomplicated chlamydia is generally managed in primary care. Referral may be necessary when the patient has suspected pelvic inflammatory disease, recurrent infection, persistent symptoms, infertility concerns, or complications involving other organ systems.
STI prevention requires patient-centered education, routine screening, early treatment, and appropriate partner management. Healthcare providers should discuss prevention strategies in a respectful, nonjudgmental manner and consider the patient’s age, sexual history, pregnancy status, and individual risk factors.
Routine screening helps identify infections that may be asymptomatic. Screening recommendations vary by infection and population. For example, annual chlamydia and gonorrhea screening is recommended for sexually active women younger than 25 years and for older women with risk factors.
Patients should be assessed for HIV and other STIs based on clinical indications and applicable screening guidelines.
Consistent and correct condom use can reduce the risk of STI transmission. Patients should understand that condoms do not eliminate all risk, particularly for infections transmitted through skin-to-skin contact.
Additional prevention strategies include reducing exposure to infected partners, discussing STI testing before new sexual relationships, and receiving recommended vaccinations such as HPV and hepatitis B vaccines when eligible.
Partner notification and treatment are important because untreated partners may transmit infection back to the patient. Healthcare providers should explain the importance of partner evaluation and follow-up testing when recommended.
Expedited partner therapy may be an option for selected infections, depending on applicable laws, clinical circumstances, and public health guidance.
Management of common sexually transmitted infections requires accurate diagnosis, appropriate antimicrobial therapy, patient education, and prevention of reinfection. Trichomoniasis is treated with metronidazole, syphilis requires stage-specific penicillin therapy, and uncomplicated chlamydia is generally treated with doxycycline in nonpregnant adults. Healthcare providers must also recognize the importance of partner treatment, follow-up testing, pregnancy considerations, and public health reporting.
Effective STI care supports individual health outcomes while reducing transmission within the community. Nurses and advanced practice providers can improve STI management by using evidence-based guidelines, providing clear counseling, and ensuring that patients understand treatment and prevention recommendations.
Centers for Disease Control and Prevention. (2021). Chlamydial infections – STI treatment guidelines. https://www.cdc.gov/std/treatment-guidelines/chlamydia.htm
Centers for Disease Control and Prevention. (2021). Syphilis – STI treatment guidelines. https://www.cdc.gov/std/treatment-guidelines/syphilis.htm
Centers for Disease Control and Prevention. (2021). Trichomoniasis – STI treatment guidelines. https://www.cdc.gov/std/treatment-guidelines/trichomoniasis.htm
Centers for Disease Control and Prevention. (2021). Sexually transmitted infections treatment guidelines, 2021. MMWR Recommendations and Reports, 70(4), 1–187. https://doi.org/10.15585/mmwr.rr7004a1
Centers for Disease Control and Prevention. (2024). Sexually transmitted infections surveillance 2023. https://www.cdc.gov/sti-statistics/annual/index.html
